Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Renal Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1549462

Unveiling the Therapeutic Potential of Berberine: Its Therapeutic Role and Molecular Mechanisms in Kidney Diseases

Provisionally accepted
Fan Zhongyu Fan Zhongyu 1,2*xuejiao wei xuejiao wei 2xiaoyu zhu xiaoyu zhu 2kun yang kun yang 2ling tian ling tian 2xiaoyan wang xiaoyan wang 2yujun du yujun du 2Liming Yang Liming Yang 2
  • 1 Jilin University, Changchun, China
  • 2 First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China

The final, formatted version of the article will be published soon.

    Berberine (BBR) is a pentacyclic benzylisoquinoline alkaloid widely distributed across various medicinal plants. Recent studies have demonstrated that berberine possesses a broad spectrum of pharmacological activities, including not only antioxidant properties but also the ability to lower blood glucose, modulate lipid profiles, and mitigate inflammation. These findings suggest that berberine holds significant potential as a therapeutic agent for renal diseases, highlighting its substantial research value. Moreover, when administered orally, berberine has been shown to exhibit a wide therapeutic safety margin. Several studies have identified berberine's renoprotective effects across a range of kidney disorders, including diabetic nephropathy, renal fibrosis, renal aging, kidney toxicity induced by chemotherapy and antibiotics. These properties underscore berberine's evolving therapeutic potential for both acute kidney injury (AKI) and chronic kidney disease (CKD). In summary, the research discussed in this article provides a comprehensive overview of the renoprotective effects of BBR and elucidates the molecular mechanisms underlying its therapeutic potential in the treatment of various renal disease. Furthermore, the article underscores the significance of berberine as a promising therapeutic agent for the treatment of kidney disorders.

    Keywords: Berberine, Renal diseases, Inflammation, Oxidative Stress, Apoptosis

    Received: 21 Dec 2024; Accepted: 05 Feb 2025.

    Copyright: © 2025 Zhongyu, wei, zhu, yang, tian, wang, du and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Fan Zhongyu, Jilin University, Changchun, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.